Press enter or spacebar to select a desired language.
Research
Press enter or spacebar to select a desired language.

PubMed COVID-19 Clinical Care

3691 - 3700 of 4611 results found

Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults

Date
Monday, May 15, 2023 - 4:00 AM
Description
CONCLUSION: Adintrevimab at doses of 300 mg IM, 500 mg IV, and 600 mg IM was well tolerated in healthy adults. Adintrevimab demonstrated dose-proportional exposure, rapid development of neutralizing antibody titers, and an extended half-life.